Dr. Cassandra Vieten's peer-reviewed academic articles and work have been cited over 5,000 times, establishing her as one of the world's leading researchers on imagination and consciousness.
Snapshot · The Mel Robbins Podcast
Dr. Cassandra Vieten's peer-reviewed academic articles and work have been cited over 5,000 times, establishing her as one of the world's leading researchers on imagination and consciousness.
Where this was said
At 3:03 · chapter starts 3:01
Mel Robbins sets the stage with a warm, high-energy introduction that promises listeners a private masterclass from a researcher whose work sits at the intersection of psychology, imagination, and consciousness. She previews the core themes: visualization, manifestation, and the science of closing the gap between where you are and where you want to be. Dr. Cassandra Vieten is introduced with her full credentials — PhD clinical psychologist, professor at UC San Diego, director of the Center for Human Imagination, director of the Center for Mindfulness at the Centers for Integrative Health, senior fellow at the Institute of Noetic Sciences, author of five books, and a researcher whose work has been cited over 5,000 times. The framing is explicitly hopeful: no matter how hard or unfair your current circumstances feel, you are not trapped. The episode, Mel promises, will give you the tools to see beyond your current reality and begin intentionally creating the life you want.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.